aTyr Pharma (NASDAQ:ATYR) Director Acquires $50,000.00 in Stock

aTyr Pharma, Inc. (NASDAQ:ATYR) Director Paul Schimmel bought 100,000 shares of the firm’s stock in a transaction on Wednesday, May 27th. The shares were bought at an average cost of $0.50 per share, with a total value of $50,000.00. Following the purchase, the director directly owned 779,143 shares in the company, valued at approximately $389,571.50. This trade represents a 14.72% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

aTyr Pharma Stock Up 11.3%

Shares of NASDAQ:ATYR opened at $0.54 on Friday. aTyr Pharma, Inc. has a 12-month low of $0.40 and a 12-month high of $7.29. The firm has a fifty day moving average of $0.74 and a two-hundred day moving average of $0.78. The firm has a market capitalization of $53.19 million, a P/E ratio of -0.74 and a beta of 0.66.

aTyr Pharma (NASDAQ:ATYR) last released its quarterly earnings data on Friday, May 15th. The company reported ($0.11) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.16) by $0.05. Equities research analysts expect that aTyr Pharma, Inc. will post -0.66 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms recently issued reports on ATYR. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of aTyr Pharma in a research note on Friday, May 22nd. Freedom Capital raised shares of aTyr Pharma from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, May 20th. Jefferies Financial Group reaffirmed a “buy” rating on shares of aTyr Pharma in a research note on Friday, March 6th. Finally, Wall Street Zen raised shares of aTyr Pharma from a “sell” rating to a “hold” rating in a research note on Sunday, May 17th. One investment analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, five have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $25.67.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. GSA Capital Partners LLP lifted its position in aTyr Pharma by 272.2% during the 4th quarter. GSA Capital Partners LLP now owns 2,630,638 shares of the company’s stock worth $2,060,000 after acquiring an additional 1,923,907 shares during the last quarter. BNP Paribas Financial Markets acquired a new position in aTyr Pharma during the 2nd quarter worth $99,000. Deutsche Bank AG lifted its position in aTyr Pharma by 3,779.5% during the 4th quarter. Deutsche Bank AG now owns 120,341 shares of the company’s stock worth $94,000 after acquiring an additional 117,239 shares during the last quarter. Creative Planning acquired a new position in aTyr Pharma during the 2nd quarter worth $74,000. Finally, Oxford Asset Management LLP acquired a new position in aTyr Pharma during the 2nd quarter worth $70,000. Institutional investors and hedge funds own 61.72% of the company’s stock.

aTyr Pharma Company Profile

aTyr Pharma, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel protein-based therapies that modulate the extracellular matrix and immune pathways. Headquartered in San Diego, California, the company applies its proprietary Extracellular Modulation® platform to identify and optimize biologic candidates for the treatment of rare and serious diseases, including pulmonary sarcoidosis, muscular dystrophy, and solid tumors.

The company’s research efforts are centered on harnessing extracellular proteins to regulate tissue remodeling, cell adhesion, and immune signaling.